Publications by authors named "Elizabeth Tarka"

Claim this Profile
N
Novel Controlled Metabolic Accelerator for Obesity-Related HFpEF: The HuMAIN-HFpEF Randomized Clinical Trial.
Ambarish Pandey, Gregory D Lewis, Barry A Borlaug, Sanjiv J Shah, Andrew J Sauer, Elizabeth A Tarka

JAMA Cardiol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EXACT Trial: Results of the Phase 1 Dose-Escalation Study.
Thomas J Povsic, Timothy D Henry, Jay H Traverse, R David Anderson, Geoffrey A Answini, Elizabeth A Tarka

Circ Cardiovasc Interv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
Astrid Yeo, Li Li, Liling Warren, Jennifer Aponte, Dana Fraser, Elizabeth Tarka

PLoS One· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease.
Emil Hagström, Claes Held, Ralph A H Stewart, Philip E Aylward, Andrzej Budaj, Elizabeth Tarka

Clin Chem· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.
Lars Wallentin, Claes Held, Paul W Armstrong, Christopher P Cannon, Richard Y Davies, Elizabeth Tarka

J Am Heart Assoc· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.
Michelle L O'Donoghue, Eugene Braunwald, Harvey D White, Mary Ann Lukas, Elizabeth Tarka

JAMA· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Darapladib for preventing ischemic events in stable coronary heart disease.

N Engl J Med· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging.
Ahmed Tawakol, Parmanand Singh, James H F Rudd, Joseph Soffer, Gengqian Cai, Elizabeth A Tarka

J Am Coll Cardiol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential effects of extended-release carvedilol and extended-release metoprolol on lipid profiles in patients with hypertension: results of the Extended-Release Carvedilol Lipid Trial.
Gregg C Fonarow, Prakash Deedwania, Vivian Fonseca, Richard W Nesto, Karol Watson, Elizabeth Tarka

J Am Soc Hypertens· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome.
Michelle L O'Donoghue, Eugene Braunwald, Harvey D White, Patrick Serruys, Ph Gabriel Steg, Elizabeth Tarka

Am Heart J· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral artery disease, biomarkers, and darapladib.
Jeffrey S Berger, Christie M Ballantyne, Michael H Davidson, Joel L Johnson, Elizabeth A Tarka

Am Heart J· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Importance of blood pressure control in left ventricular mass regression.
Alan B Miller, Nathaniel Reichek, Martin St John Sutton, Malini Iyengar, Linda S Henderson, Elizabeth A Tarka

J Am Soc Hypertens· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease.
Harvey White, Claes Held, Ralph Stewart, David Watson, Robert Harrington, Elizabeth Tarka

Am Heart J· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension.
Michael A Weber, George L Bakris, Elizabeth A Tarka, Malini Iyengar, Richard Fleck

J Clin Hypertens (Greenwich)· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Controlled-release carvedilol in the treatment of essential hypertension.
Michael A Weber, Domenic A Sica, Elizabeth A Tarka, Malini Iyengar, Richard Fleck

Am J Cardiol· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile.
George L Bakris, Elizabeth A Tarka, Brian Waterhouse, Michelle R Goulding, Anuradha Madan

Am J Cardiol· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis